Coherent Corp. Releases Second-Quarter Fiscal Year 2024 Financial Results

PITTSBURGH, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in materials, networking, and lasers, announced today the financial results for its second quarter of fiscal year 2024. These results have been posted as a letter to shareholders on the Investor Relations section of its website.

A conference call to discuss these results with Chair and CEO Dr. Vincent D. (Chuck) Mattera, Jr., and members of the management team will be held on February 6, 2024, at 8:00 a.m. ET.

The shareholder letter sets forth detailed financial information and disclosures for the company and is designed to provide greater insight into the company’s operating performance and outlook in advance of the earnings call. This format allows more time for questions and answers on the earnings call.

Please visit the Coherent investor relations website at coherent.com/company/investor-relations to view the letter to shareholders, along with accompanying supplemental financial information. Individuals wishing to listen to the live webcast of the call can access the event at the company’s website by visiting coherent.com/company/investor-relations. The call will be recorded, and a replay will be available for a limited time.

About Coherent

Coherent empowers market innovators to define the future through breakthrough technologies, from materials to systems. We deliver innovations that resonate with our customers in diversified applications for the industrial, communications, electronics, and instrumentation markets. Headquartered in Saxonburg, Pennsylvania, Coherent has research and development, manufacturing, sales, service, and distribution facilities worldwide. For more information, please visit us at coherent.com.

Contact

Paul SilversteinVice President, Investor Relations & Corporate Communications[email protected]

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
• Nvidia pitches Vera CPU to Chinese clients with August delivery target